Respiratory syncytial virus: current and emerging treatment options
| Autor: | Rohan Thompson, Benjamin T. Kopp, Grace R. Paul, Don Hayes, Lindsay C Landgrave, Tiffany L. Turner |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Palivizumab
medicine.medical_specialty Pediatrics respiratory syncytial virus viruses Economics Econometrics and Finance (miscellaneous) vitamin D Review Virus chemistry.chemical_compound Lower respiratory tract infection medicine Respiratory system Intensive care medicine business.industry Health Policy Ribavirin virus diseases Treatment options respiratory system medicine.disease Vaccination probiotics chemistry Bronchiolitis lower respiratory tract infection bronchiolitis business medicine.drug |
| Zdroj: | ClinicoEconomics and Outcomes Research: CEOR |
| ISSN: | 1178-6981 |
| DOI: | 10.2147/ceor.s60710 |
| Popis: | Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children worldwide. Although RSV typically causes mild upper respiratory infections, it frequently causes severe morbidity and mortality, especially in premature infants and children with other chronic diseases. Treatment of RSV is limited by a lack of effective antiviral treatments; however, ribavirin has been used in complicated cases, along with the addition of intravenous immune globulin in specific patients. Vaccination strategies for RSV prevention are heavily studied, but only palivizumab (Synagis(®)) has been approved for use in the United States in very select patient populations. Research is ongoing in developing additional vaccines, along with alternative therapies that may help prevent or decrease the severity of RSV infections in infants and children. To date, we have not seen a decrement in RSV morbidity and mortality with our current options; therefore, there is a clear need for novel RSV preventative and therapeutic strategies. In this review, we discuss the current and evolving trends in RSV treatment for infants and children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|